NCT05630989unknownrecruiting

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

Mandana Kamgar, MD

ClinicalTrials.gov

Enrollment · estimated

Countries · 1 sites

2027-08

Primary completion

4 mo ago

Record updated

Commercial relevance

Trial record references molecular eligibility required, ctDNA / liquid biopsy referenced, NGS / genomic profiling referenced.

Molecular eligibility requiredctDNA / liquid biopsyNGS / genomic profiling

Biomarker requirement language

3. Tumor must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician.

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
68/100
Opportunity
New unknown trial NCT05630989 posted by Mandana Kamgar, MD: "A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy".
ClinicalTrials.gov record updated 126 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

1. Age ≥18 years.
2. Diagnosis of advanced pancreatic ductal adenocarcinoma as determined by the treating physician or tumor board.
3. Tumor must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician.
4. Ability to understand a written informed consent document and the willingness to sign it.

Exclusion Criteria:

1. Age \<18 years.
2. Primary cancer diagnosis other than advanced pancreatic ductal adenocarcinoma
3. Tumor does not have a KRAS G12R mutation.